Сase of neonatal lupus in one of two children of dichorial diamniotic pregnancy in a woman with unrecognized systemic lupus erythematosus and lupus nephritis
https://doi.org/10.36485/1561-6274-2020-24-2-88-95
Abstract
The ability to realize the reproductive function for both patients with systemic lupus erythematosus and patients with a different cause of chronic kidney disease is rightfully considered as one of the most important achievements of modern medicine. The work describes the pregnancy case of the patient with systemic lupus erythematosus and secondary antiphospholipid syndrome. Renal damage with the development of renal thrombotic microangiopathy came to the fore in the clinical picture, which was regarded as nephritis and complicated the diagnosis of systemic lupus erythematosus. A positive pregnancy outcome was achieved with the development of neonatal lupus erythematosus in one twin child. The options for the prevention and treatment of thrombotic complications as well as methods for minimizing gestational complications (including preeclampsia, which the patient had in history) are discussed, inter alia, with the purposed of low-molecular-weight heparins and acetylsalicylic acid preparations. Treatment options are also described to improve the outcome of such pregnancies and to decrease the symptoms of neonatal lupus erythematosus using hydroxychloroquine. The article summarizes current management approaches for these patients with special attention to the interdisciplinary approach.
About the Authors
T. V. Kirsanova
Academician V.I. National Medical Research Center for Obstetrics, Gynecology and Perinatology Kulakova
Russian Federation
Russian Federation
Senior Researcher Tatiana V. Kirsanova MD, PhD.
117997, 4, Oparina street, Moscow
Phone: (826)2484560
N. F. Kravchenko
Academician V.I. National Medical Research Center for Obstetrics, Gynecology and Perinatology Kulakova
Russian Federation
Russian Federation
Senior Researcher Natalia F. Kravchenko, MD, PhD.
117997, 4, Oparina street, Moscow
A. I. Balakireva
Moscow State University named after M.V. Lomonosov
Russian Federation
Russian Federation
Postgraduate student Alina I. Balakireva, MD.
Faculty of Fundamental Medicine.
117192, 31-5 Lomonosovsky Prospekt, Moscow
Phone: (985)9759016
References
1. Tareeva IE. Variants of the lupous nephritis cours. Klin nephr 2011;2:5–8. (In Russ.)
2. Abdwani R, Shaqsi L, Al-Zakwani I. Neonatal and Obstetrical Outcomes of Pregnancies in Systemic Lupus Erythematosus. Oman Med J 2018;33(1):15–21. doi: 10.5001/omj.2018.04
3. Teixeira AR, Rodrigues M, Guimarães H et al. Acta Reumatol Port 2017;42(4):318–323
4. Buyon JP, Hiebert R, Copel J et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998;31(7):1658–1666. doi: 10.1016/s0735-1097(98)00161-2
5. Lee LA, Coulter S, Erner S, Chu H. Cardiac immunoglobulin deposition in congenital heart block associated with maternal anti-Ro autoantibodies. Am J Med 1987;83(4):793–796. doi: 10.1016/0002-9343(87)90918-1
6. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. Nat Clin Pract Rheumatol 2009; 5(3): 139–148. doi: 10.1038/ncprheum1018
7. Killen SA, Buyon JP, Friedman DM. Discordant spectrum of cardiac manifestations of neonatal lupus in twins. Lupus 2012; 21(5):559–562. doi: 10.1177/0961203311430512
8. Brito-Zerón P, Izmirly PM, Ramos-Casals M et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015;11(5):301–312. doi: 10.1038/nrrheum.2015.29
9. Stevens AM, Hermes HM, Lambert NC et al. Maternal and sibling microchimerism in twins and triplets discordant for neonatal lupus syndrome-congenital heart block. Rheumatology (Oxford) 2005; 44(2):187–191. doi: 10.1093/rheumatology/keh453
10. Guettrot-Imbert G, Cohen L, Fermont L et al. A new presentation of neonatal lupus: 5 cases of isolated mild endocardial fibroelastosis associated with maternal anti-SSA/Ro and anti-SSB/La antibodies. J Rheumatol 2011; 38(2):378–386. doi: 10.3899/jrheum.100317
11. Buyon JP, Clancy RM, Friedman DM. Autoimmune associated congenital heart block: integration of clinical and research clues in the management of the maternal/foetal dyad at risk. J Intern Med 2009;265(6):653–662. doi: 10.1111/j.13652796.2009.02100.x
12. Friedman DM, Kim MY, Copel JA et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008;117(4):485–493. doi: 10.1161/CIRCULATIONAHA.107.707661
13. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012;126(1):76–82. doi: 10.1161/CIRCULATIONAHA.111.089268
14. Aringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71(9):1400–1412. doi: 10.1002/art.40930
15. Kozlovskaya NL, Shilov EM, Melelera NA et al. Clinicomorphologi-cal features of nephropathy in primary and secondary antiphospholipid syndrome. Ter arh 2007;79(6):16–25. (In Russ.)
16. Kozlovskaya NL, Zakharova EV, Zverev DV et al. Combination of glomerulonephritis and antiphoslipid syndrome nephropathy in systemic lupus erirtomathosis. Nephrology and Dialysis 2007;9(4):439–446. (In Russ.)
17. Bates SM, Greer IA, Middeldorp S et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2):e691S–e736S. doi: 10.1378/chest.11-2300
18. Chighizola С, Ubiali T, Meron P. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management – An Insight into Future Approaches. J Immunol Res 2015; 2015:951424. doi: 10.1155/2015/951424
19. Chighizola CB, Gerosa M, Trespidi L et al. Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert Rev Clin Immunol 2014; 10(11):1505–2517. doi: 10.1586/1744666X.2014.968129
20. Suryanarayan D, Garcia D. Anti-Phospholipid Antibodies and Pregnancy. Ask the Hematologist Compendium 2014;11(4)
21. Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018;378(21):2010–2021. doi: 10.1056/NEJMra1705454
22. Gris JC, Bouvier S, Molinari N et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 2012;119(11):2624–2632. doi: 10.1182/blood-2011-09-381913
23. Kim MY, Buyon JP, Guerra MM et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 2016;214(1):108.e1–108. e14. doi: 10.1016/j.ajog.2015.09.066
24. Sciascia S, Hunt BJ, Talavera-Garcia E, et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol 2016;214(2):273.e1–273.e8. doi: 10.1016/j.ajog.2015.09.078
25. Sciascia S, Branch DW, Levy RA et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb Haemost 2016;115(2):285–290. doi: 10.1160/TH15-06-0491
26. Mekinian A, Lazzaroni MG, Kuzenko A et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015;14(6):498–502. doi: 10.1016/j.autrev.2015.01.012
27. Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017;76(3):476–485. doi: 10.1136/annrheumdis-2016-209770
28. Schreiber K, Breen K, Cohen H et al. HYdroxychloroquine to Improve Pregnancy Outcome in Women with AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Semin Thromb Hemost 2017;43(6):562–571. doi: 10.1055/s-0037-1603359
29. Noviani M, Wasserman S, Clowse ME. Breastfeeding in mothers with systemic lupus erythematosus. Lupus 2016; 25(9):973–979. doi: 10.1177/0961203316629555
30. Rolnik DL, Wright D, Poon LCY et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2017;50(4):492–495. doi: 10.1002/uog.18816
31. Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017;377(24): 2400. doi: 10.1056/NEJMc1713798
32. Bujold E, Roberge S, Lacasse Y et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010; 116(2 Pt 1):402–414. doi: 10.1097/AOG.0b013e3181e9322a
33. Xu TT, Zhou F, Deng CY et al. Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis. J Clin Hypertens (Greenwich) 2015;17(7):567–573. doi: 10.1111/jch.12541
Review
For citations:
Kirsanova T.V., Kravchenko N.F., Balakireva A.I. Сase of neonatal lupus in one of two children of dichorial diamniotic pregnancy in a woman with unrecognized systemic lupus erythematosus and lupus nephritis. Nephrology (Saint-Petersburg). 2020;24(2):88-95. (In Russ.) https://doi.org/10.36485/1561-6274-2020-24-2-88-95
Views:
1334
Email this article 